Grants and Giving
Alnylam funds educational initiatives to improve clinician decision-making and patient care in transthyretin-mediated amyloidosis (ATTR-CM) through evidence-based, practical, and multidisciplinary approaches.
Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (full proposal submission deadline for RFP ALNY-RFP-TTR-13)
Funding Amounts: Up to $250,000 per proposal; multiple awards possible; funding amount may differ from amount requested.
Summary: Supports independent educational initiatives to advance clinical decision-making in transthyretin-mediated amyloidosis (ATTR-CM).
Key Information: Open to organizations (not individuals); proposals must address practical clinical gaps in ATTR-CM care.
Description
This grant opportunity, offered by Alnylam Pharmaceuticals, seeks to fund independent, high-impact educational initiatives focused on advancing clinical decision-making in transthyretin-mediated amyloidosis (ATTR-CM). The program is designed to address persistent gaps in screening, diagnosis, monitoring, and management of ATTR, with an emphasis on practical, real-world clinical application and multidisciplinary care. Educational content should be evidence-based, actionable, and tailored to healthcare professionals involved in the management of ATTR-CM, such as cardiologists and clinical pharmacists.
The initiative encourages proposals that leverage interactive educational formats, digital platforms, and region-specific channels to maximize reach and relevance. The funding supports activities such as symposia at major cardiology congresses, digital CME platforms, and regional programs, with the ultimate goal of improving patient outcomes through enhanced clinician knowledge and decision-making.
